We resorted to several proven immunotherapy-related factors, including cytolytic activity (CYT) [26], IFN-γ signaling [6], antigen presenting machinery (APM) [27] and tumor infiltrating immune cells [28], to characterize the anticancer immunity. This evidence concerns the gene IFNG and neoplasm.